Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis
- 28 March 2002
- journal article
- review article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 127 (2) , 140-142
- https://doi.org/10.1159/000048186
Abstract
Systemic mastocytosis (SM) is a myeloproliferative disease affecting multipotent and/or mast cell-committed hematopoietic progenitor cells. In a significant subgroup of patients (10–35%), an associated clonal hematologic non-mast cell lineage disorder (AHNMD) occurs. These AHNMDs can be classified according to recently established WHO criteria. Most AHNMDs resemble myeloid malignancies such as acute myeloid leukemia, myeloproliferative disorders or myelodysplastic syndromes. In only a few cases, lymphoproliferative disorders are diagnosed. Patients with SM-AHNMD have a less favorable prognosis concerning survival when compared to indolent SM. No general guidelines for the treatment of patients with SM-AHNMD have been established so far. A reasonable straightforward approach may be to treat the AHNMD in those patients in the same way as if no coexisting SM exists.Keywords
This publication has 4 references indexed in Scilit:
- Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemiaBlood, 2001
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001
- Mastocytosis: molecular mechanisms and clinical disease heterogeneityLeukemia Research, 2001
- Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosisLeukemia Research, 2001